Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flutriciclamide is a small molecule radiotracer with the chemical formula C20H27FN2O2 and a molecular weight of 346.4 g/mol. It is also known by its IUPAC name (4S)-N,N-diethyl-9-(2-fluoroethyl)-5-methoxy-1,2,3,4-tetrahydrocarbazole-4-carboxamide. Flutriciclamide has been developed as a positron emission tomography (PET) imaging agent targeting the translocator protein (TSPO), which is upregulated in activated microglia and thus serves as a biomarker for neuroinflammation in various neurological diseases[6]. The compound contains a fluorine atom suitable for labeling with fluorine-18 (^18F), enabling its use in PET scans to visualize neuroinflammatory processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on flutriciclamide.